Published in PLoS One on November 09, 2011
Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med (2011) 2.29
Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis (2013) 1.51
Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis (2012) 1.39
The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis (2013) 1.19
Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis (2013) 1.03
A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology (2014) 1.03
Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 0.98
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol (2014) 0.97
Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A (2013) 0.97
A novel coding-region RNA element modulates infectious dengue virus particle production in both mammalian and mosquito cells and regulates viral replication in Aedes aegypti mosquitoes. Virology (2012) 0.94
Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets. J Infect Dis (2015) 0.91
Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A (2016) 0.90
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis (2014) 0.86
Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic. J Infect Dis (2016) 0.81
Homotypic Dengue Virus Reinfections in Nicaraguan Children. J Infect Dis (2016) 0.79
Short Report: Serological Evidence of Under-Reported Dengue Circulation in Sierra Leone. PLoS Negl Trop Dis (2016) 0.79
Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization. J Infect Dis (2015) 0.78
A novel reporter system for neutralizing and enhancing antibody assay against dengue virus. BMC Microbiol (2014) 0.77
Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response. Genome Med (2016) 0.76
Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors. J Virol (2013) 0.76
Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly. J Virol (2015) 0.75
A plasmid-based reporter system for live cell imaging of dengue virus infected cells. J Virol Methods (2014) 0.75
Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment. Curr Treat Options Infect Dis (2015) 0.75
Dengue Virus Reporter Replicon is a Valuable Tool for Antiviral Drug Discovery and Analysis of Virus Replication Mechanisms. Viruses (2016) 0.75
Pathogenesis of dengue: challenges to molecular biology. Science (1988) 14.73
Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med (2004) 8.54
Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg (1989) 4.79
The dengue viruses. Clin Microbiol Rev (1990) 4.72
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg (2001) 4.32
Antibody-enhanced dengue virus infection in primate leukocytes. Nature (1977) 4.18
Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg (1982) 4.04
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis (2004) 3.68
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A (2001) 2.86
Original antigenic sin in dengue. Am J Trop Med Hyg (1983) 2.82
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A (2006) 2.77
Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol (2006) 2.76
Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 2.73
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Dengue virus identification by the plaque reduction neutralization test. J Immunol (1967) 2.45
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg (1982) 2.41
Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol (2007) 2.15
Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg (2009) 1.93
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog (2011) 1.70
Construction and applications of yellow fever virus replicons. Virology (2005) 1.66
Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology (2008) 1.60
An infectious West Nile virus that expresses a GFP reporter gene. Virology (2005) 1.51
Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol (2004) 1.44
Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J (2007) 1.42
Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line. J Virol (2003) 1.28
An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods (2006) 1.22
An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg (2009) 1.10
Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg (2008) 1.07
Improvement in hospital indicators after changes in dengue case management in Nicaragua. Am J Trop Med Hyg (2009) 1.02
Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J Biomed Sci (2007) 0.87
Global spread and persistence of dengue. Annu Rev Microbiol (2008) 6.44
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (2011) 5.43
Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis (2003) 4.29
The WHO dengue classification and case definitions: time for a reassessment. Lancet (2006) 3.69
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg (2005) 3.12
Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol (2006) 3.07
Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol (2004) 2.83
Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis (2010) 2.80
Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol (2006) 2.76
High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop Med Int Health (2006) 2.67
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Trop Med Hyg (2005) 2.49
Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg (2006) 2.39
Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis (2010) 2.33
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32
Human enterovirus 109: a novel interspecies recombinant enterovirus isolated from a case of acute pediatric respiratory illness in Nicaragua. J Virol (2010) 2.31
Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med (2011) 2.29
Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl Trop Dis (2011) 2.26
Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin Diagn Lab Immunol (2003) 2.22
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol (2009) 2.14
Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. J Clin Virol (2008) 2.10
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg (2009) 1.87
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology (2002) 1.81
Multiple roles for separase auto-cleavage during the G2/M transition. Nat Cell Biol (2005) 1.80
Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J Immunol (2005) 1.79
Strict pairing of var promoters and introns is required for var gene silencing in the malaria parasite Plasmodium falciparum. J Biol Chem (2006) 1.78
Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J (2004) 1.77
Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis (2007) 1.71
High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl Trop Dis (2010) 1.70
Integration of information technologies in clinical studies in Nicaragua. PLoS Med (2007) 1.69
A novel magnetic bead bioassay platform using a microchip-based sensor for infectious disease diagnosis. J Immunol Methods (2006) 1.69
Convergent antibody signatures in human dengue. Cell Host Microbe (2013) 1.64
Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology (2004) 1.61
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication. J Virol (2002) 1.60
Animal models of dengue virus infection. Viruses (2012) 1.60
Single-reaction, multiplex, real-time rt-PCR for the detection, quantitation, and serotyping of dengue viruses. PLoS Negl Trop Dis (2013) 1.57
Prevalence and seasonality of influenza-like illness in children, Nicaragua, 2005-2007. Emerg Infect Dis (2009) 1.55
Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. Virology (2005) 1.55
Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology (2008) 1.54
Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe (2010) 1.53
Virus identification in unknown tropical febrile illness cases using deep sequencing. PLoS Negl Trop Dis (2012) 1.52
An infectious West Nile virus that expresses a GFP reporter gene. Virology (2005) 1.51
Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis (2013) 1.51
Quantitative assessment of the benefits of specific information technologies applied to clinical studies in developing countries. Am J Trop Med Hyg (2008) 1.49
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Vertebrate cells genetically deficient for Cdc14A or Cdc14B retain DNA damage checkpoint proficiency but are impaired in DNA repair. J Cell Biol (2010) 1.44
Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J (2007) 1.42
Clinical attack rate and presentation of pandemic H1N1 influenza versus seasonal influenza A and B in a pediatric cohort in Nicaragua. Clin Infect Dis (2010) 1.40
Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis (2012) 1.39
RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication. J Virol (2006) 1.38
Y box-binding protein-1 binds to the dengue virus 3'-untranslated region and mediates antiviral effects. J Biol Chem (2007) 1.37
A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med (2014) 1.37
Comparison of the FDA-approved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed assay for dengue virus detection and serotyping. J Clin Microbiol (2013) 1.35
The capsid-coding region hairpin element (cHP) is a critical determinant of dengue virus and West Nile virus RNA synthesis. Virology (2008) 1.31
Interplay of RNA elements in the dengue virus 5' and 3' ends required for viral RNA replication. J Virol (2010) 1.31
Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. Virology (2004) 1.30
Development of an internally controlled real-time reverse transcriptase PCR assay for pan-dengue virus detection and comparison of four molecular dengue virus detection assays. J Clin Microbiol (2013) 1.29
Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol (2005) 1.26
Early clinical features of dengue virus infection in nicaraguan children: a longitudinal analysis. PLoS Negl Trop Dis (2012) 1.25
Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol (2012) 1.25
Sustainable transfer of biotechnology to developing countries: fighting poverty by bringing scientific tools to developing-country partners. Ann N Y Acad Sci (2007) 1.25
Poly(A)-binding protein binds to the non-polyadenylated 3' untranslated region of dengue virus and modulates translation efficiency. J Gen Virol (2009) 1.25
Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology (2008) 1.24
Report of an NIAID workshop on dengue animal models. Vaccine (2010) 1.23
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol (2011) 1.22
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci (2009) 1.20
End-to-end communication in the modulation of translation by mammalian RNA viruses. Virus Res (2005) 1.20
Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One (2011) 1.20
Dengue virus modulates the unfolded protein response in a time-dependent manner. J Biol Chem (2011) 1.20
A review of biochars' potential role in the remediation, revegetation and restoration of contaminated soils. Environ Pollut (2011) 1.19
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses (2008) 1.19
The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis (2013) 1.19
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
Dengue virus utilizes a novel strategy for translation initiation when cap-dependent translation is inhibited. J Virol (2006) 1.17
Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol Dis (2010) 1.14
Epigenetic centromere specification directs aurora B accumulation but is insufficient to efficiently correct mitotic errors. J Cell Biol (2010) 1.13
Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120. ChemMedChem (2006) 1.11
Unusual dengue virus 3 epidemic in Nicaragua, 2009. PLoS Negl Trop Dis (2011) 1.10
Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. J Mol Recognit (2009) 1.10
Oscillating kissing stem-loop interactions mediate 5' scanning-dependent translation by a viral 3'-cap-independent translation element. RNA (2006) 1.10
Index cluster study of dengue virus infection in Nicaragua. Am J Trop Med Hyg (2010) 1.08
Conformational changes in the solution structure of the dengue virus 5' end in the presence and absence of the 3' untranslated region. J Virol (2008) 1.07
Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc (2009) 1.07